CStone Pharmaceuticals Reports 97.54% Revenue Growth in 2022, Driven by Drug Sales and Licensing Fees
China-based CStone Pharmaceuticals (HKG: 2616) released its 2022 financial report, recording total revenues of RMB...
Henlius’ OX40 Monoclonal Antibody HLX51 Gains NMPA Approval for Phase I Clinical Study
Shanghai Henlius Biotech, Inc (HKG: 2696) has announced that it has received approval from the...
Boao Lecheng and Shanghai Biomed Center Form Long-Term Partnership for Medical Innovation
The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has entered into a long-term...
Haisco Pharmaceutical’s EGFR-PROTAC HSK40118 Gains NMPA Approval for Clinical Trials
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received clinical...
Astellas Pharma’s Xtandi Gains Momentum in China with Positive Phase III ARCHES Study Results
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that its prostate cancer therapy, Xtandi (enzalutamide),...
World Orphan Drug Alliance Expands to China with RareStone Group Partnership
The World Orphan Drug Alliance (WODA) has announced its expansion to China for the first...
MabPharm Files NDA for CMAB009, Biosimilar to Erbitux, Targeting Metastatic Colorectal Cancer
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the filing of...
Neowise Biotechnology Secures RMB 200 Million in Series A+ Financing Round
Neowise Biotechnology Co., Ltd, a T cell receptor (TCR)-therapy developer based in Suzhou, reportedly raised...
Singde Yiyang Secures Series A Financing to Expand Wellness Services in China
Singde Yiyang, a leading wellness service provider based in Qingdao, reportedly raised “hundreds of millions”...
NMPA Releases 65th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 65th batch of reference drugs for...
NHSA Launches Crackdown on Medical Insurance Fund Management with New Inspection Measures
The National Healthcare Security Administration (NHSA) is intensifying efforts to manage medical insurance funds at...
Meinian Onehealth and Astra Biotechnology Partner on Hypersensitive Blood Biomarker Detection
China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with...
Immorna Enrolls First Patient in Phase I Study of JCXH-211 for Malignant Tumors
Immorna (Hangzhou) Biotechnology, an mRNA-based vaccine developer based in Hangzhou, has announced the enrollment of...
CDE Issues Guidelines on Single-Arm Clinical Trials for Antitumor Drugs
The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for the Applicability of...
XtalPi and DP Technology Partner to Accelerate Pre-Clinical Drug Development with AI
Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a partnership with Beijing-based DP...
Laekna Therapeutics Files for IPO on Hong Kong Stock Exchange, Aims to Expand Cancer and Hepatic Fibrosis Therapies
China’s Laekna Therapeutics Shanghai Co., Ltd has filed for an initial public offering (IPO) with...
LanssonPharm’s Anti-Depression Drug LS21031 Receives CDE Approval for Clinical Trials
China-based central nervous system (CNS) drug developer LanssonPharm has announced that it has received clinical...
GSK’s Nucala Gains NMPA Approval for Severe Eosinophilic Asthma in China
UK-based GSK plc (NYSE: GSK) has announced that a market approval filing for Nucala (mepolizumab)...
Juventas Cell Therapy’s CNCT19 Receives FDA IND Approval for r/r B-ALL Treatment
China-based Juventas Cell Therapy Ltd’s chimeric antigen receptor (CAR) T-cell therapy, CNCT19 (Inaticabtagene Autoleucel), has...
Bio-Thera Solutions Initiates First Patient Dosing in Phase I Study of BAT8007
China-based Bio-Thera Solutions, Ltd. (SHA: 688177) has announced the first patient dosing in a multi-center,...